Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA ...

SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating

Related Keywords

Japan ,United Kingdom ,Tokyo ,Ryogoku ,Chiba ,Naomi Eichenbaum ,Jula Inrig ,Nivi Nehra ,Nasdaq ,Travere Therapeutics Inc ,International Symposium On Iga Nephropathy ,Corporate Communications ,Exchange Commission ,International Symposium ,Iga Nephropathy ,United Kingdom National Registry ,Rare Renal Diseases ,Incident Patients With Iga Nephropathy ,First Line Therapy ,Interim Findings From ,Clinical Trial ,Greater Extent Than ,Disease Progression ,Important Safety ,Endothelin Receptor Antagonists ,Upper Limit ,Fetal Toxicity ,Kidney Injury ,Angiotensin System ,Acid Reducing Agents ,Steroidal Anti Inflammatory Agents ,Including Selective ,Increasing Serum Potassium ,Reproductive Potential ,Full Prescribing Information ,Travere Therapeutics ,Private Securities Litigation Reform Act ,Region ,